ZA7.F · Larimar Therapeutics, Inc

-

Please sign in to comment on ZA7.F

1 Comment

Admin

4 years ago

Larimar Therapeutics, Inc is currently in a long term downtrend where the price is trading 16.5% below its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the sector with a price to sales ratio of 0.0.

Larimar Therapeutics, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.

Its net income has increased by 50.4% to $-4M since the same quarter in the previous year.

Finally, its free cash flow grew by 2.3% to $-10M since the same quarter in the previous year.

Based on the above factors, Larimar Therapeutics, Inc gets an overall score of 3/5.

Exchange	F
CurrencyCode	EUR
ISIN	None
Sector
Industry

Market Cap	3M
PE Ratio	None
Target Price	None
Dividend Yield	0.0%
Beta	0.27

ABOUT

Larimar Therapeutics, Inc

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases. The company's lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare and progressive genetic disease. Larimar Therapeutics, Inc. is headquartered in Bala Cynwyd, Pennsylvania.

ZA7.F · Larimar Therapeutics, Inc

-

Larimar Therapeutics, Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Larimar Therapeutics, Inc using a moving average strategy